| ATCT Main | Editorial Board | Current Issue | Infocus Roundtable | ATCT CME Activities | Download | Search |
Immunotoxins: The Next Generation
File name: atct_v4n4RP_ft.pdf
File size: (3) pages, [180 KB]
Biomarkers of Response to VEGFTargeted Therapy Found in Renal Cell Carcinoma
File name: atct_v4n4RP_rr01.pdf
File size: (1) page, [116 KB]
Genetic Assay Advances Treatment Options in GIST
File name: atct_v4n4RP_rr02.pdf
File size: (1) page, [116 KB]
Novel Vaccine Shows Promise in Breast Cancer
File name: atct_v4n4RP_rr03.pdf
File size: (1) page, [116 KB]
Panitumumab Approved for Metastatic Colorectal Carcinoma
File name: atct_v4n4RP_rr04.pdf
File size: (1) page, [116 KB]
New Uses and Warning for Imatinib
File name: atct_v4n4RP_rr05.pdf
File size: (1) page, [116 KB]
Bevacizumab Use Expanded to Lung Cancer
File name: atct_v4n4RP_rr05.pdf
File size: (1) page, [116 KB]
Trastuzumab Indications Now Include Adjuvant Use
File name: atct_v4n4RP_rr05.pdf
File size: (1) page, [116 KB]
FDA Approves Histone Deactylase Inhibitor, Vorinostat
File name: atct_v4n4RP_rr05.pdf
File size: (1) page, [116 KB]
Targeted Mouse Models May Advance Cancer Drug Development
File name: atct_v4n4RP_dg.pdf
File size: (2) pages, [120 KB]
New Cancer-Related Mutations Found in Breast & Colon Cancers
File name: atct_v4n4RP_nc.pdf
File size: (1) page, [156 KB]
Article reprints are provided as a service to oncology profressionals as part of the Advances in Targeted Cancer Therapies website (www.targetedtherapies.org). Reprints are not for commercial distribution.
Presentation: (10) Slides, notes and references included
File name: atct02_2004.ppt [1.9 MB]
![]() |
View entire presentation |
|
The notion that cancer might be slowed or halted by blocking the vasculature that nourishes a tumor has been studied for decades with frustratingly little success. Recent advances, however, have finally resulted in the clinical development of several classes of promising angiogenesis inhibitors. This slide set reviews the angiogenic mechanisms that constitute targets for this approach to cancer therapy and outlines how the various agents in development exert their effects. Any or all of these slides may be used by oncology professionals to enhance and customize educational and informational presentations on angiogenesis inhibition.
Presentation: (7) Slides, notes and references included
File name: atct01_2003.ppt [2.0 MB]
![]() |
View entire presentation |
|
Inhibition of the epidermal growth factor receptor (EGFR) is currently a therapeutic strategy of keen interest in oncology. Many tumor types express or overexpress EGFR. A growing number of compounds, both antibodies and small molecules, have been developed to target various points along the EGFR pathway. In the interests of helping clinicians understand the biology and mechanisms of this novel approach to cancer therapy, this slide set represents a visual primer that may be used to enhance and customize educational and informational presentations on EGFR inhibition.